BioLineRx Company Profile (NASDAQ:BLRX)

About BioLineRx

BioLineRx logoBioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BLRX
  • CUSIP:
Key Metrics:
  • Previous Close: $1.27
  • 50 Day Moving Average: $1.02
  • 200 Day Moving Average: $1.01
  • 52-Week Range: $0.71 - $1.42
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.17
  • P/E Growth: 0.00
  • Market Cap: $71.67M
  • Outstanding Shares: 56,432,000
  • Beta: 0.58
Profitability:
  • Return on Equity: -36.69%
  • Return on Assets: -34.08%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 11.73%
  • Quick Ratio: 11.73%
Additional Links:
Companies Related to BioLineRx:

Analyst Ratings

Consensus Ratings for BioLineRx (NASDAQ:BLRX) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $3.01 (133.67% upside)

Analysts' Ratings History for BioLineRx (NASDAQ:BLRX)
Show:
DateFirmActionRatingPrice TargetDetails
2/15/2017HC WainwrightInitiated CoverageBuy$3.00View Rating Details
2/13/2017Rodman & RenshawInitiated CoverageBuy$3.00View Rating Details
11/28/2016Roth CapitalReiterated RatingBuy$7.00View Rating Details
11/22/2016Maxim GroupSet Price TargetHold$1.00View Rating Details
9/23/2016S&P Equity ResearchLower Price Target$1.24 -> $1.10View Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$3.50 -> $3.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$3.50 -> $3.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for BioLineRx (NASDAQ:BLRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/22/2016Q316($0.07)($0.08)ViewN/AView Earnings Details
5/17/2016Q116($0.08)($0.10)ViewListenView Earnings Details
3/10/2016Q415($0.06)($0.07)ViewListenView Earnings Details
11/16/2015Q315($0.08)($0.03)ViewListenView Earnings Details
8/20/2015Q215($0.10)($0.09)ViewListenView Earnings Details
5/18/2015Q115($0.10)($0.08)ViewListenView Earnings Details
11/10/2014Q314($0.17)($0.01)ViewN/AView Earnings Details
8/6/2014Q214($0.09)($0.12)ViewN/AView Earnings Details
5/20/2014Q114($0.11)($0.01)ViewN/AView Earnings Details
3/17/2014($0.15)($0.20)ViewN/AView Earnings Details
11/13/2013($0.18)($0.20)ViewN/AView Earnings Details
8/6/2013Q213($0.02)ViewN/AView Earnings Details
5/7/2013($0.02)($0.20)ViewN/AView Earnings Details
11/14/2012Q312($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioLineRx (NASDAQ:BLRX)
Current Year EPS Consensus Estimate: $-0.28 EPS
Next Year EPS Consensus Estimate: $-0.18 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.08)($0.08)($0.08)
Q2 20161($0.07)($0.07)($0.07)
Q3 20161($0.07)($0.07)($0.07)
Q4 20161($0.08)($0.08)($0.08)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioLineRx (NASDAQ:BLRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BioLineRx (NASDAQ:BLRX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for BioLineRx (NASDAQ:BLRX)
DateHeadline
News IconStock Price of BioLineRx Ltd. (BLRX) Increases 15.61% - Highland Mirror (NASDAQ:BLRX)
www.highlandmirror.com - February 21 at 9:33 AM
News IconIs The Sell-Side Predicting That BioLineRx Ltd. (NASDAQ:BLRX) Will Move Higher? - Winfield Review (NASDAQ:BLRX)
winfieldreview.com - February 16 at 5:42 AM
News IconBioLineRx Ltd. (NASDAQ:BLRX) Daily Sentiment Score At 0.103 - Stock Observer (NASDAQ:BLRX)
www.thestockobserver.com - February 16 at 5:42 AM
News IconNews Review: BioLineRx, Ltd. (NASDAQ:BLRX), Sierra Wireless Inc. (NASDAQ:SWIR) - The Newburgh Press (NASDAQ:BLRX)
newburghpress.com - February 14 at 9:33 PM
News IconBioLineRx Ltd. (BLRX) stock coverage initiated with “Buy” in note to investors by Rodman & Renshaw - The Ledger Gazette (NASDAQ:BLRX)
ledgergazette.com - February 14 at 9:33 PM
News IconThe Sierra Wireless, Inc. (SWIR) Sees Large Volume Increase Following Strong Earnings (NASDAQ:BLRX)
fairydetox.org - February 14 at 4:30 PM
News IconTechnical Trading: Focus on Shares of Biolinerx Ltd. (BLRX) - Rives Journal (NASDAQ:BLRX)
rivesjournal.com - February 13 at 9:28 PM
News IconBioline RX Ltd (BLRX) is Initiated by Rodman & Renshaw to “Buy ... - Highland Mirror (NASDAQ:BLRX)
www.highlandmirror.com - February 13 at 9:28 PM
finance.yahoo.com logoCoverage initiated on BioLineRx by Rodman & Renshaw (NASDAQ:BLRX)
finance.yahoo.com - February 13 at 9:28 PM
News IconBurning Stock on the move: BioLineRx, Ltd. (NASDAQ:BLRX) - HugoPress (NASDAQ:BLRX)
hugopress.com - February 10 at 8:29 PM
News IconForward Earnings Estimate of BioLineRx Ltd.(BLRX) - Highland Mirror (NASDAQ:BLRX)
www.highlandmirror.com - February 10 at 3:27 PM
News IconInvestor Center: Technical Watch for Biolinerx Ltd. (BLRX) - Piedmont Register (NASDAQ:BLRX)
piedmontregister.com - February 8 at 9:12 PM
finance.yahoo.com logoBioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14 (NASDAQ:BLRX)
finance.yahoo.com - February 7 at 4:55 PM
News IconAverage Directional Index in Review for Biolinerx Ltd. (BLRX) - Sherwood Daily (NASDAQ:BLRX)
sherwooddaily.com - February 2 at 2:12 AM
News IconStock Watch: Indicators in View for Biolinerx Ltd. (BLRX) - Sherwood Daily (NASDAQ:BLRX)
sherwooddaily.com - January 31 at 4:12 PM
News IconTraders are Taking a Closer Look at These Shares: Biolinerx Ltd. (BLRX) - Sherwood Daily (NASDAQ:BLRX)
sherwooddaily.com - January 30 at 8:50 PM
News IconThese Two Stocks in Motion: BioLineRx, Ltd. (NASDAQ:BLRX), Booz Allen Hamilton Holding Corporation (NYSE:BAH) - The Newburgh Press (NASDAQ:BLRX)
newburghpress.com - January 30 at 8:50 PM
seekingalpha.com logoBioLine Rx: This Under-The-Radar Biotech Stock Is A Strong Buy At $1 (NASDAQ:BLRX)
seekingalpha.com - January 28 at 3:57 PM
News IconADX, MA, and RSI in Focus for Biolinerx Ltd. (BLRX) - Sherwood Daily (NASDAQ:BLRX)
sherwooddaily.com - January 27 at 4:18 PM
News IconEarnings in Full Force, Analysts Take Aim at BioLineRx Ltd. (NASDAQ:BLRX) - Wall Street Beacon (NASDAQ:BLRX)
wsbeacon.com - January 27 at 2:39 AM
News IconWhat Are the Technicals Saying About These Shares: Biolinerx Ltd. (BLRX) - Sherwood Daily (NASDAQ:BLRX)
sherwooddaily.com - January 26 at 4:36 PM
News IconInvesting Focus: Indicators in View on Shares of Biolinerx Ltd. (BLRX) - Sherwood Daily (NASDAQ:BLRX)
sherwooddaily.com - January 23 at 8:32 PM
News IconShould You Sell BioLineRx Ltd. Based On Current Broker Views? - NewsDen (NASDAQ:BLRX)
newsden.net - January 23 at 3:31 PM
News IconIs There a Catalyst Out There For BioLine Rx Ltd (NASDAQ:BLRX) - Prospect Journal (NASDAQ:BLRX)
prospectjournal.com - January 20 at 10:02 PM
News IconSorting Out the Technicals on Shares of Biolinerx Ltd. (BLRX) - Sherwood Daily (NASDAQ:BLRX)
sherwooddaily.com - January 19 at 8:38 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on BioLineRx Ltd. (NASDAQ:BLRX) - Wall Street Beacon (NASDAQ:BLRX)
wsbeacon.com - January 19 at 3:37 PM
finance.yahoo.com logoBioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda (NASDAQ:BLRX)
finance.yahoo.com - January 19 at 3:37 PM
smarteranalyst.com logoStock Update (NASDAQ:BLRX): Here’s Why Bioline RX Ltd Shares Soaring 11% (NASDAQ:BLRX)
www.smarteranalyst.com - January 19 at 1:25 AM
News IconChart Indicator Check on Shares of Biolinerx Ltd. (BLRX) - Sherwood Daily (NASDAQ:BLRX)
sherwooddaily.com - January 18 at 3:22 PM
News IconShort Interest Worth Watching: Will Biolinerx Limited Ads (NASDAQ:BLRX) Run Out of Steam Soon? Short Interest Is ... - Baxley Report (NASDAQ:BLRX)
baxleyreport.com - January 18 at 3:22 PM
streetinsider.com logoBioLineRx (BLRX) Initiates Second Phase 2a Trial of BL-8040 (NASDAQ:BLRX)
www.streetinsider.com - January 18 at 2:44 AM
News IconTechnical Tracker: Watching Shares of Biolinerx Ltd. (BLRX) - Sherwood Daily (NASDAQ:BLRX)
sherwooddaily.com - January 17 at 4:41 PM
streetinsider.com logoBioLineRx (BLRX) Initiates Second Phase 2a Trial of BL-8040 - StreetInsider.com (NASDAQ:BLRX)
www.streetinsider.com - January 17 at 4:41 PM
us.rd.yahoo.com logoBioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer (NASDAQ:BLRX)
us.rd.yahoo.com - January 17 at 9:33 AM
News IconWill The Needle Move For BioLineRx Ltd. (NASDAQ:BLRX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:BLRX)
wsbeacon.com - January 14 at 8:57 PM
us.rd.yahoo.com logo7:59 am BioLineRx in slides details expected milestones in 2017/2018 (NASDAQ:BLRX)
us.rd.yahoo.com - January 9 at 5:02 PM
finance.yahoo.com logoBioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco (NASDAQ:BLRX)
finance.yahoo.com - January 4 at 4:37 PM
News IconBargain Hunter Investor Update on BioLineRx, Ltd. (NASDAQ:BLRX) - Prospect Journal (NASDAQ:BLRX)
prospectjournal.com - December 23 at 4:06 PM
News IconIs This a Sensible Stock at Current Levels: BioLineRx, Ltd. (NASDAQ:BLRX) - Prospect Journal (NASDAQ:BLRX)
prospectjournal.com - December 23 at 2:00 AM
News IconAre Investors Shying Away from BioLineRx, Ltd. (NASDAQ:BLRX ... - Prospect Journal (NASDAQ:BLRX)
prospectjournal.com - December 22 at 9:00 PM
News IconAre There Any Catalysts to Propel Shares of BioLineRx, Ltd. (NASDAQ:BLRX) - Prospect Journal (NASDAQ:BLRX)
prospectjournal.com - December 21 at 3:36 PM
News IconBoom or Bust? Is there any value in BioLineRx, Ltd. (NASDAQ:BLRX) - Prospect Journal (NASDAQ:BLRX)
prospectjournal.com - December 21 at 2:23 AM
News IconStock Propelling Higher as it is Gapping up: BioLineRx, Ltd. (NASDAQ:BLRX) - Prospect Journal (NASDAQ:BLRX)
prospectjournal.com - December 20 at 6:54 AM
News IconBioLineRx Ltd. (NASDAQ:BLRX) Daily Sentiment Score At 0.046 - Stock Observer (NASDAQ:BLRX)
www.thestockobserver.com - December 14 at 3:27 PM
News IconBioLineRx Ltd. (BLRX) Valuation According To Analysts - UK Market News (NASDAQ:BLRX)
www.ukmarketnews.co.uk - December 9 at 9:15 PM
News IconBioLineRx Ltd. (NASDAQ:BLRX) Bearish Target At $7 - Stock Observer (NASDAQ:BLRX)
www.thestockobserver.com - December 9 at 9:15 PM
News IconBioLineRx Ltd. (NASDAQ:BLRX) Quarterly EPS Seen At $-0.08 - Stock Observer (NASDAQ:BLRX)
www.thestockobserver.com - December 7 at 2:12 AM
streetinsider.com logoBioLineRx (BLRX) Presents Positive Phase 2a Correlative and ... - StreetInsider.com (NASDAQ:BLRX)
www.streetinsider.com - December 5 at 10:46 AM
finance.yahoo.com logoBioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016 (NASDAQ:BLRX)
finance.yahoo.com - December 5 at 10:46 AM
finance.yahoo.com logo7:01 am BioLineRx presents positive Phase 2a correlative data for BL-8040 at the ongoing 58th American Society of Hematology Annual Meeting (NASDAQ:BLRX)
finance.yahoo.com - December 5 at 10:45 AM

Social

What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

Where is BioLineRx's stock going? Where will BioLineRx's stock price be in 2017?

6 brokers have issued 1 year price objectives for BioLineRx's shares. Their predictions range from $1.00 to $7.00. On average, they expect BioLineRx's stock price to reach $3.01 in the next twelve months.

What are analysts saying about BioLineRx stock?

Here are some recent quotes from research analysts about BioLineRx stock:

  • According to Zacks Investment Research, "Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. " (11/24/2016)

  • Maxim Group analysts commented, "BioLineRx announced a collaboration with Genentech (Roche) to evaluate BL-8040 in combination with Genentech’s checkpoint inhibitor atezolizumab (PD-L1) in multiple solid tumors, as well as in AML (acute myeloid leukemia)." (9/7/2016)

Who owns BioLineRx stock?

BioLineRx's stock is owned by a number of of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (1.84%), Alyeska Investment Group L.P. (1.14%) and Opaleye Management Inc. (0.44%).

Who bought BioLineRx stock? Who is buying BioLineRx stock?

BioLineRx's stock was purchased by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P..

How do I buy BioLineRx stock?

Shares of BioLineRx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BioLineRx stock cost?

One share of BioLineRx stock can currently be purchased for approximately $1.29.

BioLineRx (NASDAQ:BLRX) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for BioLineRx (NASDAQ:BLRX)

Earnings History Chart

Earnings by Quarter for BioLineRx (NASDAQ:BLRX)

Dividend History Chart

Dividend Payments by Quarter for BioLineRx (NASDAQ:BLRX)

Last Updated on 2/22/2017 by MarketBeat.com Staff